Automated bone scan index predicts survival in metastatic castration-resistant prostate cancer patients

This study prospectively validates the potential usefulness and establishes the prognostic value of an automated system for evaluating bone metastases, according to Fred Saad, MD.

The automated bone scan index (aBSI) was predictive of overall survival in univariate analysis, and remained significant in multivariate analysis, Dr. Saad noted in an editorial accompanying the study.

Despite some limitations, the system provides an encouraging framework to build on, he noted.

“With ongoing and future work in validating aBSI, this technology could eventually be introduced in clinical practice and research settings for improved stratification,” he wrote in the editorial.

Now, researchers are integrating Prostate Cancer Working Group progression criteria into the aBSI framework, which could be useful for evaluating response and resistance to treatment, if validated.

“This is extremely important for anyone who realizes the time and effort required for comparing bone scans to determine whether or not patients are progressing on clinical trials,” Dr. Saad wrote.

Dr. Saad is the University of Montreal Endowed Chair in Prostate Cancer, Surgery, University of Montreal Hospital Center. These comments are derived from his editorial in JAMA Oncology . Dr. Saad had no reported conflict of interest related to the editorial.